Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for people with untreated PD-L1-positive metastatic non-small-cell lung cancer.
Status In progress
Decision Selected
Process STA 2018
ID number 3762

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
21 October 2020 - 18 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 March 2020 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual